Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

Inclusion criteria

• HIV patients >18 years old who provide signed and dated informed consent;
• Males and females;
• SOT recipients (heart, liver or kidney);
• On stable antiretroviral therapy (ART) for ≥6 months preceding the screening visit;
• Plasma HIV RNA <50 cop/ml for 12 months (2 tests separated by at least 12 months with no viral load >50 between determinations);
• Absence of major reverse transcriptase or integrase gene mutations affecting study drug efficacy by proviral DNA sequencing

Exclusion criteria

• HIV patients who have stopped ART due to virological failure;
• HIV patients who require treatment with DTG contraindicated medications;
• History or presence of an allergy or intolerance to the study drug;
• Active opportunistic infection;
• Neoplasms requiring chemotherapy.
• Pregnancy or breast feeding or planned pregnancy during the study period
• Any other contraindication to study drugs.